Caribou Biosciences (CRBU) Competitors $1.10 +0.05 (+4.76%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRBU vs. VERV, ORKA, ABVX, RVNC, SANA, FULC, RAPP, ATAI, URGN, and ORICShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Verve Therapeutics (VERV), Oruka Therapeutics (ORKA), ABIVAX Société Anonyme (ABVX), Revance Therapeutics (RVNC), Sana Biotechnology (SANA), Fulcrum Therapeutics (FULC), Rapport Therapeutics (RAPP), Atai Life Sciences (ATAI), UroGen Pharma (URGN), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Verve Therapeutics Oruka Therapeutics ABIVAX Société Anonyme Revance Therapeutics Sana Biotechnology Fulcrum Therapeutics Rapport Therapeutics Atai Life Sciences UroGen Pharma ORIC Pharmaceuticals Caribou Biosciences (NASDAQ:CRBU) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership. Which has preferable valuation and earnings, CRBU or VERV? Caribou Biosciences has higher earnings, but lower revenue than Verve Therapeutics. Verve Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.92M10.32-$102.07M-$1.62-0.68Verve Therapeutics$59.61M6.89-$200.07M-$2.11-2.18 Do institutionals & insiders have more ownership in CRBU or VERV? 77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 8.3% of Caribou Biosciences shares are owned by company insiders. Comparatively, 19.3% of Verve Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor CRBU or VERV? In the previous week, Verve Therapeutics had 15 more articles in the media than Caribou Biosciences. MarketBeat recorded 21 mentions for Verve Therapeutics and 6 mentions for Caribou Biosciences. Verve Therapeutics' average media sentiment score of 0.85 beat Caribou Biosciences' score of 0.36 indicating that Verve Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verve Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CRBU or VERV? Caribou Biosciences has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Is CRBU or VERV more profitable? Verve Therapeutics has a net margin of -807.65% compared to Caribou Biosciences' net margin of -1,290.81%. Verve Therapeutics' return on equity of -35.23% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,290.81% -45.46% -38.07% Verve Therapeutics -807.65%-35.23%-27.65% Does the MarketBeat Community prefer CRBU or VERV? Verve Therapeutics received 6 more outperform votes than Caribou Biosciences when rated by MarketBeat users. However, 62.79% of users gave Caribou Biosciences an outperform vote while only 61.11% of users gave Verve Therapeutics an outperform vote. CompanyUnderperformOutperformCaribou BiosciencesOutperform Votes2762.79% Underperform Votes1637.21% Verve TherapeuticsOutperform Votes3361.11% Underperform Votes2138.89% Do analysts prefer CRBU or VERV? Caribou Biosciences presently has a consensus target price of $7.40, suggesting a potential upside of 572.73%. Verve Therapeutics has a consensus target price of $25.75, suggesting a potential upside of 458.57%. Given Caribou Biosciences' higher probable upside, equities analysts plainly believe Caribou Biosciences is more favorable than Verve Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Verve Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVerve Therapeutics beats Caribou Biosciences on 10 of the 17 factors compared between the two stocks. Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.31M$2.97B$5.43B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.6731.5826.8320.05Price / Sales10.32429.82393.98117.08Price / CashN/A168.6838.2534.62Price / Book0.263.376.874.61Net Income-$102.07M-$72.17M$3.22B$248.19M7 Day Performance34.33%18.10%6.76%2.97%1 Month Performance38.31%20.85%13.66%16.58%1 Year Performance-64.40%-24.45%18.27%8.16% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.8297 of 5 stars$1.10+4.8%$7.40+572.7%-64.9%$102.31M$9.92M-0.67100VERVVerve Therapeutics3.5705 of 5 stars$4.37-5.6%$25.75+489.2%-22.5%$389.56M$59.61M-1.78110Trending NewsEarnings ReportAnalyst RevisionGap UpORKAOruka Therapeutics2.6307 of 5 stars$10.31+2.5%$39.86+286.6%N/A$386.02MN/A-1.65N/ANews CoverageEarnings ReportAnalyst RevisionABVXABIVAX Société Anonyme2.6356 of 5 stars$5.88-2.2%$34.00+478.2%-58.1%$381.15MN/A0.0061Positive NewsRVNCRevance Therapeutics1.9473 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500SANASana Biotechnology2.4868 of 5 stars$1.68-3.7%$10.80+542.9%-75.8%$378.80MN/A-1.20380Trending NewsGap UpFULCFulcrum Therapeutics0.7728 of 5 stars$6.93+0.7%$4.50-35.1%-15.5%$374.07M$80M-22.35100RAPPRapport Therapeutics1.8136 of 5 stars$10.19+2.3%$32.67+220.6%N/A$371.92MN/A-2.95N/APositive NewsATAIAtai Life Sciences2.3817 of 5 stars$1.84+11.5%$10.50+470.7%+18.5%$367.62M$308,000.00-2.2780News CoverageEarnings ReportAnalyst ForecastURGNUroGen Pharma4.1257 of 5 stars$7.97+9.0%$32.86+312.3%-41.6%$367.47M$91.87M-2.53200High Trading VolumeORICORIC Pharmaceuticals4.5136 of 5 stars$5.14+8.7%$19.17+272.9%-37.6%$365.39MN/A-2.8280Positive News Related Companies and Tools Related Companies Verve Therapeutics Competitors Oruka Therapeutics Competitors ABIVAX Société Anonyme Competitors Revance Therapeutics Competitors Sana Biotechnology Competitors Fulcrum Therapeutics Competitors Rapport Therapeutics Competitors Atai Life Sciences Competitors UroGen Pharma Competitors ORIC Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBU) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
